IDDI speaking at the Annual Meeting of the Society for Clinical Trials (SCT)
May 17, 2021 — May 20, 2021
IDDI presenting two sessions at the Clinical Trials Annual Meeting
The 42ND ANNUAL MEETING of the Society for Clinical Trials (SCT) will focus on Advancing Rigorous and Ethical Trials in the Pandemic Era.
Marc Buyse, ScD gave a talk on “RECENT DEVELOPMENTS IN QUANTITATIVE BENEFIT-RISK ASSESSMENT IN CLINICAL TRIALS” on May 18, 2021.
In this session Dr. Buyse focused on the recent development of generalized pairwise comparisons (GPC) for benefit-risk assessment. GPC uses all pairwise comparisons between two patients in different treatment arms in terms of one or several prioritized outcomes. Examples of GPC include “net treatment benefit” (difference between the proportion of pairs in favor of treatment less the proportion in favor of control) and “win ratio” (proportion of pairs in favor of treatment over the proportion of pairs in favor of control). Pairwise comparisons can incorporate thresholds of clinical relevance, enable several outcomes to be analyzed simultaneously, and can be used flexibly for the benefit risk assessment of therapeutic interventions.
VIEW PRESENTATION The Net Benefit of a treatment should take the correlation between benefits and harms into account
- Marc Buyse introduced the keynote session on the “David Sackett Trial of the Year”: The prestigious David Sackett Trial of the Year Award awarded the RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial led by the University of Oxford on May 20.
In this year meeting, Marc Buyse, ScD, CSO of IDDI was recognized for his outstanding service as Chair of the Trial of the Year Committee